A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed. With Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \<18 years old with advanced melanoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dzieci w wieku od 6 miesięcy do poniżej 18 lat.
- •Potwierdzony typ raka (czerniak, guz lity lub chłoniak), który jest w zaawansowanym stadium, powrócił po leczeniu lub nie zareagował na wcześniejsze leczenie.
- •Dostępna tkanka guza do badań.
- •Rak, który nie może być usunięty operacyjnie lub na który nie ma skutecznego standardowego leczenia.
- •Ogólny dobry stan zdrowia dziecka pozwalający na udział w badaniu (oceniany m.in. przez skalę sprawności).
✗ Disqualifies
- •Aktualny udział w innym badaniu leku lub urządzeń medycznych.
- •Leczenie innymi lekami, które mogą wpływać na wyniki tego badania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 6 Months
- Maximum age
- 17 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
Call for Information (Investigational Site 0019)
Aurora, United States
Call for Information (Investigational Site 0024)
Chicago, United States
Call for Information (Investigational Site 0026)
Boston, United States
Call for Information (Investigational Site 0031)
New York, United States
Call for Information (Investigational Site 0070)
Fargo, United States
Call for Information (Investigational Site 0071)
Sioux Falls, United States
Call for Information (Investigational Site 0054)
Dallas, United States
MSD Brasil
São Paulo, Brazil
MSD France
Paris, France
MSD Sharp & Dohme GmbH
München, Germany
Merck Sharp & Dohme Co. Ltd.
Hod HaSharon, Israel
MSD Italia S.r.l.
Rome, Italy
Merck Sharp & Dohme Lda.
Paço de Arcos, Portugal
MSD Korea LTD
Seoul, South Korea
MSD Sweden
Stockholm, Sweden
Merck Sharp & Dohme Ltd.
London, United Kingdom
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.